Cancer immunotherapy, alone or in combination with conventional therapies, has revolutionized the landscape of antineoplastic treatments, with dendritic cells (DC) emerging as key orchestrators of anti-tumor immune responses. Among the distinct DC subsets, conventional type 1 dendritic cells (cDC1) have gained prominence due to their unique ability to cross-present antigens and activate cytotoxic T lymphocytes. This review summarizes the distinctive characteristics of cDC1, their pivotal role in anticancer immunity, and the potential applications of cDC1-based strategies in immunotherapy.
Christian A. Luber, Jürgen Cox, Henning Lauterbach, Ben Fancke, Matthias Selbach, Jürg Tschopp, Akira Shizuo, Marian Wiegand, Hubertus Hochrein, Meredith O’Keeffe, Matthias Mann
Jenny Sprooten, Jolien Ceusters, An Coosemans, Patrizia Agostinis, Steven De Vleeschouwer, Laurence Zitvogel, Guido Guido Kroemer, Lorenzo Galluzzi, Abhishek D. Garg
Discussion(0)
No comments yet. Be the first to comment.